2,5-Dimethoxyamphetamine

Last updated

2,5-Dimethoxyamphetamine
2,5-DMA.svg
Clinical data
Other names2,5-DMA; 2,5-Dimethoxy-α-methylphenethylamine; DMA; DMA-4; DOH; NSC-367445
Routes of
administration 		Oral [1] [2]
Drug class Serotonin 5-HT2A receptor agonist
Pharmacokinetic data
Duration of action 6–8 hours [1] [2]
Identifiers
  • 1-(2,5-dimethoxyphenyl)propan-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.018.673 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H17NO2
Molar mass 195.262 g·mol−1
3D model (JSmol)
  • CC(CC1=C(C=CC(=C1)OC)OC)N
  • InChI=1S/C11H17NO2/c1-8(12)6-9-7-10(13-2)4-5-11(9)14-3/h4-5,7-8H,6,12H2,1-3H3
  • Key:LATVFYDIBMDBSY-UHFFFAOYSA-N

2,5-Dimethoxyamphetamine (2,5-DMA), also known as DMA-4 or as DOH, is a drug of the phenethylamine and amphetamine families. [1] [2] It is one of the dimethoxyamphetamine (DMA) series of positional isomers. [1] [2] The drug is notable in being the parent compound of the DOx (4-substituted-2,5-dimethoxyamphetamine) series of drugs. [1] [2]

Contents

Use and effects

2,5-DMA is said to be inactive as a psychedelic, at least at the doses that have been assessed. [1] [2] However, it has been reported to produce some stimulant-like effects, as well as sympathomimetic effects and mydriasis. [1] [2] [3] The dose range is said to be 80 to 160 mg orally and its duration is 6 to 8 hours. [1] [2] However, it has also been said to be active with stimulant-like effects at a dose of 50 mg. [3]

Pharmacology

2,5-DMA activities
Target Affinity (Ki, nM)
5-HT1A 2,583
5-HT1B 8,435 (rat)
5-HT1D ND
5-HT1E ND
5-HT1F ND
5-HT2A 211–5,200 (Ki)
160–3,548 (EC50 Tooltip half-maximal effective concentration)
58–109% (Emax Tooltip maximal efficacy)
5-HT2B 1,039 (Ki)
3,390–>10,000 (EC50)
93% (Emax)
5-HT2C 104–>10,000 (Ki)
3,144 (EC50)
76% (Emax)
5-HT3 ND
5-HT4 ND
5-HT5A ND
5-HT6 ND
5-HT7 ND
α1A–α1D ND
α2A–α2C ND
β1, β2 ND
D1 ND
D2 >7,000
D3–D5 ND
H1–H4 ND
M1–M5 ND
TAAR1 >10,000 (EC50) (human)
I1 ND
σ1, σ2 ND
SERT Tooltip Serotonin transporter>7,000 (Ki)
ND (IC50 Tooltip half-maximal inhibitory concentration)
ND (EC50)
NET Tooltip Norepinephrine transporter>7,000 (Ki)
ND (IC50)
ND (EC50)
DAT Tooltip Dopamine transporter>7,000 (Ki)
ND (IC50)
ND (EC50)
MAO-A Tooltip Monoamine oxidase A>100,000 (IC50)
MAO-B Tooltip Monoamine oxidase B>100,000 (IC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [4] [5] [6] [7] [8] [9]
[10] [11] [12] [13] [14] [15]

2,5-DMA is a low-potency serotonin 5-HT2A receptor partial agonist, with an affinity (Ki) of 2,502 nM, an EC50 Tooltip half-maximal effective concentration of 160 to 3,548 nM (depending on the signaling cascade and study), and an Emax Tooltip maximal efficacy of 66 to 109%. [7] [8] [11] [12] It has also been assessed at several other receptors. [7] [8] In a much earlier study, its affinities (Ki) were 1,020 nM at the serotonin 5-HT1 receptor and 5,200 nM at the serotonin 5-HT2 receptor. [16] [17] The drug does not appear to bind to the monoamine transporters, at least at the assessed concentrations (up to 7,000 nM). [7] [8] It was inactive at the human trace amine-associated receptor 1 (TAAR1). [7] [8] 2,5-DMA shows dramatically reduced potency as a serotonin 5-HT2A receptor agonist compared to the DOx drugs, such as 2,5-dimethoxy-4-methylamphetamine (DOM). [7] [8]

2,5-DMA substitutes for DOM in rodent drug discrimination tests, albeit with dramatically lower potency than other DOx drugs, suggesting that it may have psychedelic-like effects at very high doses. [18] It also substitutes for 5-MeO-DMT in rodent drug discrimination tests. [19] Conversely, 2,5-DMA shows no substitution for dextroamphetamine in such tests, suggesting that it lacks psychostimulant- or amphetamine-like effects, at least in rodents. [18]

Though 2,5-DMA appears to be inactive or of very low potency as a psychedelic in humans, it is a highly potent anti-inflammatory drug similarly to other DOx and 2C drugs. [12] [20] This was in spite of it being of very low potency as a serotonin 5-HT2A receptor agonist in terms of calcium mobilization in the study (EC50 = 3,548 nM; Emax = 109.0%). [12] Based on the preceding findings, Charles D. Nichols has said that both fully anti-inflammatory non-psychedelic compounds like 2,5-DMA and fully psychedelic non-anti-inflammatory compounds like DOTFM are known. [20]

Manufacturing

2,5-DMA is used by Polaroid Corporation in the manufacturing of Polaroid film. [3] [21] [22]

See also

References

  1. 1 2 3 4 5 6 7 8 Shulgin AT, Shulgin A (1991). "#54 2,5-DMA; DMA; 2,5-DIMETHOXYAMPHETAMINE". PiHKAL: A Chemical Love Story (1st ed.). Berkeley, CA: Transform Press. ISBN   9780963009609. OCLC   25627628.
  2. 1 2 3 4 5 6 7 8 Shulgin A, Manning T, Daley PF (2011). "#36. 2,5-DMA". The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds . Vol. 1. Berkeley: Transform Press. ISBN   978-0-9630096-3-0.
  3. 1 2 3 Shulgin AT (1978). "Psychotomimetic Drugs: Structure-Activity Relationships". In Iversen LL, Iversen SD, Snyder SH (eds.). Stimulants. Boston, MA: Springer US. pp. 243–333. doi:10.1007/978-1-4757-0510-2_6. ISBN   978-1-4757-0512-6. Although 2,5-DMA has no medical utility and has thus been classified as a Schedule I drug by the Drug Enforcement Administration, there is a considerable demand for it as a chemical in the photographic industry. The manufacturing quota for it, for a single year's production, is 45,000,000 g as the free base (Anon., 1976), and this magnitude of commercial production, in addition to the inexpensive availability of the synthetic precursor 1-(2,5-dimethoxyphenyl)-2-nitropropene, may have accounted for its appearance in high purity and broad availability in the period prior to its legal proscription.
  4. ↑ "Kᵢ Database". PDSP. 15 March 2025. Retrieved 15 March 2025.
  5. ↑ Liu T. "BindingDB BDBM50005251 (+/-)2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine::1-(2,5-dimethoxyphenyl)propan-2-amine::2,5-dimethoxy-4-bromoamphetamine::2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine::2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine(2,5-DMA)::CHEMBL8642::DMA". BindingDB. Retrieved 15 March 2025.
  6. ↑ Nelson DL, Lucaites VL, Wainscott DB, Glennon RA (January 1999). "Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors" . Naunyn Schmiedebergs Arch Pharmacol. 359 (1): 1–6. doi:10.1007/pl00005315. PMID   9933142.
  7. 1 2 3 4 5 6 Luethi D, Rudin D, Hoener MC, Liechti ME (2022). "Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted 2,5-Dimethoxyamphetamines". The FASEB Journal. 36 (S1) fasebj.2022.36.S1.R2691. doi: 10.1096/fasebj.2022.36.S1.R2691 . ISSN   0892-6638.
  8. 1 2 3 4 5 6 Rudin D, Luethi D, Hoener MC, Liechti ME (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal. 36 (S1) fasebj.2022.36.S1.R2121. doi: 10.1096/fasebj.2022.36.S1.R2121 . ISSN   0892-6638.
  9. ↑ Hemanth P, Nistala P, Nguyen VT, Eltit JM, Glennon RA, Dukat M (2023). "Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors". Frontiers in Pharmacology. 14 1101290. doi: 10.3389/fphar.2023.1101290 . PMC   9902381 . PMID   36762110.
  10. ↑ Dowd CS, Herrick-Davis K, Egan C, DuPre A, Smith C, Teitler M, et al. (August 2000). "1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists" . J Med Chem. 43 (16): 3074–3084. doi:10.1021/jm9906062. PMID   10956215.
  11. 1 2 Pottie E, Cannaert A, Stove CP (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Arch Toxicol. 94 (10): 3449–3460. Bibcode:2020ArTox..94.3449P. doi:10.1007/s00204-020-02836-w. hdl: 1854/LU-8687071 . PMID   32627074.
  12. 1 2 3 4 Flanagan TW, Billac GB, Landry AN, Sebastian MN, Cormier SA, Nichols CD (April 2021). "Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore". ACS Pharmacol Transl Sci. 4 (2): 488–502. doi:10.1021/acsptsci.0c00063. PMC   8033619 . PMID   33860179. The nature of the 4-position substituent of phenethylamine psychedelics has been previously linked to 5-HT2 receptor selectivity as well as agonist properties at 5-HT2 receptors.40 Analysis of the 4-position demonstrated that the identity of the moiety at this position was rather flexible. Fully efficacious substitutions at the 4-position included the halogens iodine and bromine (R)-DOI (Figure 3), 2C-B (Figure 7A), methoxy (TMA-2) (Figure 7G), short-chain hydrocarbons (R)-DOM (Figure 7H), (R)-DOET) (Figure 7I), and a branched hydrocarbon (DOiBu) (Figure 7J). [...] In a comparison of PenH-AUC values determined for each drug as a proxy measure of anti-inflammatory efficacy (Figure 8A) to either EC50 or EMax for calcium mobilization downstream of 5- HT2A receptor activation (Table 1), [...]
  13. ↑ Acuña-Castillo C, Villalobos C, Moya PR, Sáez P, Cassels BK, Huidobro-Toro JP (June 2002). "Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors". Br J Pharmacol. 136 (4): 510–519. doi:10.1038/sj.bjp.0704747. PMC   1573376 . PMID   12055129.
  14. ↑ Runyon SP, Mosier PD, Roth BL, Glennon RA, Westkaemper RB (November 2008). "Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation". J Med Chem. 51 (21): 6808–6828. doi:10.1021/jm800771x. PMC   3088499 . PMID   18847250.
  15. ↑ Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Frontiers in Pharmacology. 10 1590. doi: 10.3389/fphar.2019.01590 . PMC   6989591 . PMID   32038257.
  16. ↑ Glennon RA (January 1987). "Central serotonin receptors as targets for drug research". J Med Chem. 30 (1): 1–12. doi:10.1021/jm00384a001. PMID   3543362. Table II. Affinities of Selected Phenalkylamines for 5-HT1 and 5-HT2 Binding Sites
  17. ↑ Shannon M, Battaglia G, Glennon RA, Titeler M (June 1984). "5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA)". Eur J Pharmacol. 102 (1): 23–29. doi:10.1016/0014-2999(84)90333-9. PMID   6479216.
  18. 1 2 Glennon RA (1989). "Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships" (PDF). NIDA Res Monogr. 94: 43–67. PMID   2575229. Archived from the original (PDF) on May 11, 2023.
  19. ↑ Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology (Berl). 68 (2): 155–158. doi:10.1007/BF00432133. PMID   6776558.
  20. 1 2 Hamilton Morris (14 November 2021). "PODCAST 33: An interview with Dr. Charles D. Nichols". The Hamilton Morris Podcast (Podcast). Patreon. Event occurs at 48:22–53:56. Retrieved 20 January 2025.
  21. ↑ "Erowid Psychoactive Vault : DEA Federal Register". erowid.org. Retrieved 10 May 2025.
  22. ↑ "Manufacturer of Controlled Substances; Notice of Registration". Federal Register. 25 April 2000. Retrieved 10 May 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.